# **Human NDUFB9 Knockdown Cell Line (WB-Validated)**



**Catalog #: C62276** 

#### **Aliases**

NDUFB9; NADH:Ubiquinone Oxidoreductase Subunit B9; UQOR22; LYRM3; B22; NADH Dehydrogenase (Ubiquinone) 1 Beta Subcomplex, 9, 22kDa; NADH Dehydrogenase [Ubiquinone] 1 Beta Subcomplex Subunit 9; NADH-Ubiquinone Oxidoreductase B22 Subunit; LYR Motif-Containing Protein 3; Complex I B22 Subunit; CI-B22; NADH Dehydrogenase (Ubiquinone) 1 Beta Subcomplex, 9 (22kD, B22); Complex I-B22; MC1DN24

# **Background**

Gene Name: NDUFB9 NCBI Gene Entry: 4715

# **Storage**

Store at liquid nitrogen for 1 year.

# **Kit Components**

- 1. Human NDUFB9 Knockdown Cell Line (Wb-Validated)
- 2. Wild-type cell line

### **Parental Cell Line**

Human cell line supplied by the client

### **Validation Methods**

RT-qPCR, Western blotting (WB)

# **Shipping**


Shipped on Dry Ice.

#### **Instructions For Use**


This knockdown cell line should be paired with wild-type cell line for use.

**Note:** This product is for research use only.

#### Validation Data



RT-qPCR analysis. HeLa cells were infected with NDUFB9-specific shRNA lentiviral particles, total RNA was extracted from wild-type and knockdown cells, RT-qPCR was performed using gene-specific primers.  $\Delta$ Ct (CtKD-CtWT) was used to calculate mRNA reduction (%) between wild-type and knockdown cells using the following formula:  $(1-1/2\Delta$ Ct) x 100%.



Western blotting analysis. NDUFB9 protein expression in wild-type (WT) and shRNA knockdown (KD) HeLa cells was detected using Western blotting. Hsp90  $\alpha$  served as a loading control. The blots were incubated with primary antibodies against NDUFB9 and Hsp90  $\alpha$ , respectively, followed by incubating with HRP-conjugated goat anti-rabbit secondary antibody. Images were developed using FeQ<sup>TM</sup> ECL Substrate Kit.